Sanjeewa Seneviratne|Ian Campbell|Nina Scott|Marion Kuper?Hommel|Boa Kim|Avinesh Pillai|Ross Lawrenson
Adherence to adjuvant endocrine therapy: Is it a factor for ethnic differences in breast cancer outcomes in New Zealand?
University of Auckland|University of Auckland|Waikato District Health Board|Waikato District Health Board|Waikato Hospital|University of Auckland|University of Auckland
despite benefits adjuvant endocrine therapy hormone receptor positive breast cancer many women nonadherent discontinue endocrine treatment early studied differences adherence adjuvant endocrine therapy ethnicity cohort new zealand women breast cancer impact breast cancer outcomeswe analysed data women n 1149 newly diagnosed hormone receptor positive nonmetastatic invasive breast cancer treated adjuvant endocrine therapy waikato 20052011 linked data waikato breast cancer registry national pharmaceutical database examined identify differences ethnicity adherence adjuvant endocrine therapy effect suboptimal adherence cancer recurrence mortalityoverall high level adherence 80 observed among 704 women declined 768 593 first fifth year treatment mori women significantly likely suboptimally adherent 80 compared european women crude rate 37 vs 28 p 0005 adjusted 151 95 ci 104217 suboptimal adherence associated significantly higher risk breast cancer mortality hr 177 95 ci 105299 recurrence hr 214 95 ci 146314suboptimal adherence adjuvant endocrine therapy likely contributor breast cancer mortality inequity mori european women highlights need future research identify effective ways increase adherence mori women